As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.

But camizestrant’s use could depend on uptake of monitoring – for now.

Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.

DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.

In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.

BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.

Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.

Any hopes of differentiation could come down to side effects.

Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.